Table 1.
Patient characteristics and clinical status for patient-derived xenografts
| Xenograft | Age at diagnosis, mo/sex | ALL subtype | Disease status at biopsy | Length of CR1, mo | Survival after relapse, mo | Current clinical status |
|---|---|---|---|---|---|---|
| ALL-2 | 65/F | c-ALL | Relapse 3 | 30 | 46 | DOD |
| ALL-3 | 154/F | Pre-B | Diagnosis | 38 | 212* | CR2 |
| ALL-4 | 105/M | Ph+ | Diagnosis | 10 | 1 | DOD |
| ALL-7 | 88/M | Biphen. | Diagnosis | 7 | 6 | DOD |
| ALL-8 | 152/M | T-ALL | Relapse 1 | 17 | 1 | DOD |
| ALL-10 | 48/M | c-ALL | Diagnosis | 138* | — | CR1 |
| ALL-11 | 37/F | c-ALL | Diagnosis | 204* | — | CR1 |
| ALL-16 | 122/F | T-ALL | Diagnosis | 63* | — | CR1 |
| ALL-17 | 107/F | c-ALL | Diagnosis | 25 | 165* | CR2 |
| ALL-19 | 194/M | c-ALL | Relapse 1 | 4 | 7 | DOD |
| ALL-27 | 104/M | T-ALL | Diagnosis | 10 | 19 | DOD |
| ALL-29 | 59/M | T-ALL | Diagnosis | 137* | — | CR1 |
| ALL-30 | 90/M | T-ALL | Diagnosis | 13 | — | DOD |
| ALL-31 | 123/M | T-ALL | Diagnosis | 5 | — | DOD |
| ALL-32 | 135/M | T-ALL | Relapse 1 | 10 | 68* | CR2 |
| ALL-33 | 89/M | T-ALL | Diagnosis | 73* | — | CR1 |
| ALL-42 | 32/M | T-ALL | Diagnosis | 16 | 5 | DOD |
Biphen, biphenotypic; c-ALL, common (CD10+) BCP-ALL; CR1, complete remission 1; CR2, complete remission 2; DOD, dead of disease; F, female; M, male; Pre-B, BCP-ALL.
*
No event (censored according to most recent clinic visit).